A topical cannabis product development company headquartered in Vancouver and Las Vegas has recently had some success protecting its intellectual property in the U.S.
On Wednesday, Ovation Science Inc. (CSE: OVAT) (OTCQB: OVATF) announced that the U.S. Patent and Trademark Office had provided it with a patent entitled: Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and 9-tetrahydracannabinol (THC).
The new patent will be valid until 2041 and covers the company’s proprietary THC and CBD transdermal creams along with its Invisicare drug delivery system (see specifics below).
Read more: EndoCanna partners with Biostrap for new custom-tailored therapeutics solution
Read more: CBD usage booming among baby boomers: Stirling
The patent will ensure protection of Ovation’s product composition along with its method for formulating a transdermal delivery composition in accordance with a preferred ratio of CBD to THC through the skin tissue. The company has also filed for similar patent protection of its intellectual property in Canada.
“The granting of this patent helps solidify our position in the marketplace with products that cannot be duplicated by competitors,” said Terry Howlett, CEO of Ovation Science.
“We have proven that our transdermal delivery method is more effective than other topical products on the market and more efficient than edibles (gummies, etc.) or inhalation (smoking or vaping) as it has better absorption; avoiding ‘first-pass’ through the liver. First-pass increases the delivery time and makes less CBD:THC available than Ovation’s formulations.”
Ovation says that its Invisicare skin delivery technology has had more than 20 years of research and development. The company also claims that studies have proven its creams will release 10 times more CBD into the skin with far superior penetration than other products.